GHDDI Launches “AI KongMing” Drug Discovery Platform in Beijing, Pioneering a New Paradigm of End-to-End AI-Driven Drug Discovery
Beijing, December 11, 2025 — Today, the Global Health Drug Discovery Institute (GHDDI) successfully hosted the themed event “AI KongMing: Steering the Future of Drug Discovery” in Beijing, officially unveiling “AI KongMing,” a domestically developed artificial intelligence platform that achieves end-to-end intelligent design across the entire drug discovery process.
Dr. Manchun Lu, Chief Operating Officer of GHDDI, delivering the opening remarks
The launch of AI KongMing marks a major breakthrough for China in the field of AI-enabled, end-to-end drug discovery, representing a landmark achievement in applying artificial intelligence to life sciences and advancing next-generation productive forces. As China’s first open AI drug discovery platform built on principles of equity, accessibility, and global health impact, AI KongMing focuses on addressing critical diseases such as malaria, tuberculosis, and viral infections. The platform is designed to empower the global research community by significantly improving the efficiency and success rates from target discovery to clinical candidate development, with particular emphasis on accelerating drug innovation for neglected global health priorities.
Breaking Technical Barriers: AI KongMing Enables Fully AI-Driven Drug Design
After years of sustained investment in AI-enabled drug discovery, GHDDI has successfully integrated global top-tier resources to independently develop AI KongMing, a comprehensive AI platform capable of supporting the entire drug discovery workflow. The platform seamlessly covers the full chain from target structure analysis → AI-based molecular generation & optimization → activity evaluation →druggability assessment, effectively connecting critical stages of early drug discovery.
Built around the core concept of end-to-end intelligent drug design, AI KongMing delivers an integrated AI system encompassing target structure analysis, molecular generation, activity prediction, druggability assessment, and multi-objective optimization. Leveraging the collective knowledge base of leading global research institutions and GHDDI’s years of real-world R&D data accumulation, the platform digitally reconstructs fragmented biological, chemical, and pharmacological knowledge into an AI-driven productivity engine that is reasoning-capable, generative, and continuously evolving.
At the algorithmic level, AI KongMing integrates multiple proprietary technologies, including generative AI molecular design models, high-precision virtual screening, and multi-objective ADMET evaluation models, forming an intelligent closed-loop across design, screening, evaluation, optimization, and decision-making. This architecture dramatically reduces the repetitive trial-and-error cycles inherent in traditional drug discovery. The platform has been systematically validated across dozens of real-world R&D pipelines spanning tuberculosis, malaria, and rare diseases, achieving several-fold to orders-of-magnitude improvements in hit rates and optimization efficiency compared with conventional approaches.
To meet the stringent data security and computing requirements of biomedical research, AI KongMing is built on a fully controllable and secure infrastructure, supporting on-premise and private cloud deployment to ensure compliant, secure, and controlled handling of core research data. While adhering to GHDDI’s public-interest mission, the platform is also made openly accessible to the global academic and industrial communities, fostering a new AI-enabled drug discovery paradigm led by China’s independent innovation.
Unlike many market offerings that focus on isolated steps of the drug discovery process, AI KongMing is purpose-built for real-world R&D scenarios, deeply integrating the practical expertise of biologists, medicinal chemists, and pharmacokinetic scientists. Powered by a large language model (LLM)-based multi-agent engine, the platform connects the entire chain from target identification to design, screening, evaluation, and optimization through intelligent agents. This approach systematically overcomes long-standing data silos and workflow fragmentation, while enabling continuous learning and iterative improvement within live R&D pipelines.
As a result, complex computational drug design capabilities are transformed into a platformized, intelligent, and inclusive research infrastructure, empowering frontline scientists and elevating advanced computational drug discovery from expert-dependent tools to a scalable, reproducible foundation for scientific innovation and new-quality productivity.
Dr. Jinjiang Guo, Head of Data Science at GHDDI, and his team demonstrating efficient drug design using the “AI KongMing” platform
Mission-Driven Innovation: Advancing Global Health Through Technology Philanthropy
Professor Sheng Ding, Director of GHDDI, elaborated on the mission and vision underpinning AI KongMing:
“The launch of AI KongMing represents a systematic demonstration of China’s scientific capabilities in the frontier field of AI drug discovery, proving that we can build independent infrastructure covering the entire drug discovery pipeline. But for GHDDI, technological breakthroughs are not the end goal. As a non-profit organization, our original intention in developing AI KongMing has always been to address the most urgent yet underserved needs in global health—diseases that affect millions worldwide but lack sufficient commercial investment.”
Guided by the principles of open collaboration, GHDDI called on global academic institutions, pharmaceutical companies, biotechnology firms, and research organizations to join the AI KongMing co-development network, expanding its application across diseases and use cases.
GHDDI looks forward to working with research partners from diverse backgrounds to continuously refine the platform through real-world practice, jointly advancing this open infrastructure toward maturity and building a more inclusive, sustainable ecosystem for science-driven public good.
Panel Discussion Participants
Manchun Lu, PhD — Chief Operating Officer, GHDDI
Rumin Zhang, PhD — Chief Scientific Officer, GHDDI
Jinjiang Guo, PhD — Head of Data Science, GHDDI
Haiguang Liu, PhD — Chief Scientist & Director of Research, Beijing Zhongguancun Academy
Wanqing He, PhD — Partner & VP, Qingcheng Jizhi; Former Head of High-Performance Computing at Alibaba Cloud; Intel Principal Engineer
AI KongMing Platform: https://datascience.ghddi.org
